Margaret A. Foley

643 citations

14 papers · 402 indexed · h-index 6

Pulmonary and Respiratory Medicine top 10%
Oncology top 10%
Cancer Research
Molecular Biology
Radiology, Nuclear Medicine and Imaging

Co-authors: Julie D. Horan Jiuzhou Wang Nasser K. Altorki Frances A. Shepherd Karen Kelly Mary O’Brien Wilfried Eberhardt Philip C. Hoffman
Topics: Lung Cancer Treatments and Mutations (9 papers)Lung Cancer Diagnosis and Treatment (5 papers)Lung Cancer Research Studies (4 papers)
Cited by: Pulmonary and Respiratory Medicine Oncology Cancer Research
Journals: Journal of Clinical Oncology International Journal of Radiation Oncology*Biology*Physics Annals of Oncology
Partner nations: United States Canada United Kingdom

In The Last Decade

Margaret A. Foley

13 papers receiving 394 citations

Peers

Countries citing papers authored by Margaret A. Foley

Since Specialization

Citations

This map shows the geographic impact of Margaret A. Foley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margaret A. Foley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margaret A. Foley more than expected).

Fields of papers citing papers by Margaret A. Foley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margaret A. Foley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margaret A. Foley. The network helps show where Margaret A. Foley may publish in the future.

Co-authorship network of co-authors of Margaret A. Foley

This figure shows the co-authorship network connecting the top 25 collaborators of Margaret A. Foley. A scholar is included among the top collaborators of Margaret A. Foley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margaret A. Foley. Margaret A. Foley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Evaluating the cost-effectiveness of the Prostate Cancer Patient Empowerment Program 2025 ·Canadian Urological Association Journal ·(unknown),G. Ilie,Ricardo Rendon,Ross Mason,Mohammad Hajizadeh,(unknown),Margaret A. Foley,Andrea Kokorovic,Nikhilesh Patil,David Bowes,(unknown),Derek Wilke,(unknown),(unknown)	0
2	Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study 2016 ·Journal of Neuro-Oncology ·Regina I. Jakacki,Margaret A. Foley,Julie D. Horan,Jiuzhou Wang,Mark W. Kieran,Daniel C. Bowers,Éric Bouffet,Stergios Zacharoulis,Stan Gill	20
3	Final follow-up (f/u) results from RADIANT: A randomized double blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection in patients (pts) with stage IB–IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC). 2015 ·Journal of Clinical Oncology ·Mary O’Brien,Karen Kelly,Nasser K. Altorki,Wilfried Eberhardt,David R. Spigel,Lucio Crinò,Chun‐Ming Tsai,Joo-Hang Kim,Eun Kyung Cho,Philip C. Hoffman,Shaf Keshavjee,Sergey Orlov,Piotr Serwatowski,Joe Wang,Margaret A. Foley,Julie D. Horan,Frances A. Shepherd	2
4	Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America 2015 ·The Prostate ·Anthony M. Joshua,Neal D. Shore,Fred Saad,Kim N.,Carl A. Olsson,Urban Emmenegger,Mark C. Scholz,William R. Berry,Som D. Mukherjee,Eric Winquist,Naomi B. Haas,Margaret A. Foley,Carl Dmuchowski,Frank Perabo,Mohammad Hirmand,Nahla Hasabou,Dana E. Rathkopf,(unknown)	16
5	Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC. 2015 ·Journal of Clinical Oncology ·Helena A. Yu,Geoffrey R. Oxnard,Alexander I. Spira,Leora Horn,Jared Weiss,Yan Feng,Howard West,Giuseppe Giaccone,Tracey L. Evans,Ronan J. Kelly,(unknown),Srinivasu Poondru,Fei Jie,Koji Aoyama,Margaret A. Foley,(unknown),Anne Keating,Andrew Krivoshik	12
6	Common and rare EGFR mutations (EGFRm) in the RADIANT trial: Final follow-up with 5 year data. 2015 ·Journal of Clinical Oncology ·Frances A. Shepherd,Wilfried Eberhardt,Nasser K. Altorki,Mary O’Brien,Joe Wang,(unknown),Stan Gill,Kenneth K. Iwata,Frank C. Richardson,Julie D. Horan,Margaret A. Foley,Karen Kelly	3
7	Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial 2015 ·Journal of Clinical Oncology ·Karen Kelly,Nasser K. Altorki,Wilfried Eberhardt,Mary O’Brien,David R. Spigel,Lucio Crinò,Chun-Ming Tsai,Joo-Hang Kim,Eun Kyung Cho,Philip C. Hoffman,С. В. Орлов,Piotr Serwatowski,Jiuzhou Wang,Margaret A. Foley,Julie D. Horan,Frances A. Shepherd	283
8	A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results. 2014 ·Journal of Clinical Oncology ·Karen Kelly,Nasser K. Altorki,Wilfried Eberhardt,Mary O’Brien,David R. Spigel,Lucio Crinò,Chun‐Ming Tsai,Joo-Hang Kim,Eun Kyung Cho,Aleksandra Szczęsna,Otto C. Burghuber,Philip C. Hoffman,Shaf Keshavjee,Sergey Orlov,Piotr Serwatowski,Jiuzhou Wang,Margaret A. Foley,Julie D. Horan,Jung Wook Park,Frances A. Shepherd,(unknown)	37
9	Analysis of treatment duration and safety of adjuvant erlotinib (E) versus placebo (P) after surgery in patients (pts) with non-small cell lung cancer (NSCLC): RADIANT trial. 2014 ·Journal of Clinical Oncology ·Mary O’Brien,Wilfried Eberhardt,Nasser K. Altorki,David R. Spigel,Lucio Crinò,Chun‐Ming Tsai,Eun Kyung Cho,Joo-Hang Kim,Aleksandra Szczęsna,Philip C. Hoffman,Otto C. Burghuber,Shaf Keshavjee,Sergey Orlov,Piotr Serwatowski,Jiuzhou Wang,Margaret A. Foley,Julie D. Horan,Jung Wook Park,Frances A. Shepherd,Karen Kelly,(unknown)	2
10	Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. 2014 ·Journal of Clinical Oncology ·Anthony M. Joshua,Neal D. Shore,Fred Saad,Kim N.,Carl A. Olsson,Urban Emmenegger,Mark C. Scholz,William R. Berry,Som D. Mukherjee,Eric Winquist,Naomi B. Haas,Nahla Hasabou,Carl Dmuchowski,Frank Perabo,Mohammad Hirmand,Margaret A. Foley,Dana E. Rathkopf,(unknown)	2
11	Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial. 2014 ·Journal of Clinical Oncology ·Frances A. Shepherd,Nasser K. Altorki,Wilfried Eberhardt,Mary O’Brien,David R. Spigel,Lucio Crinò,Chun‐Ming Tsai,Joo-Hang Kim,Eun Kyung Cho,Aleksandra Szczęsna,Otto C. Burghuber,Philip C. Hoffman,Shaf Keshavjee,Sergey Orlov,Piotr Serwatowski,Jiuzhou Wang,Margaret A. Foley,Julie D. Horan,Frank C. Richardson,Karen Kelly,(unknown)	16
12	Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results 2014 ·International Journal of Radiation OncologyBiologyPhysics ·Nasser K. Altorki,Mary O’Brien,Wilfried Eberhardt,Frank C. Richardson,(unknown),Margaret A. Foley,Julie D. Horan,Frances A. Shepherd,Karen Kelly	2
13	Prognostic and Predictive Roles of Egfr Copy Number and Kras Mutation Status from the Radiant Trial of Adjuvant Erlotinib (E) Versus Placebo (P) 2014 ·Annals of Oncology ·Frances A. Shepherd,Nasser K. Altorki,Wilfried Eberhardt,Mary O’Brien,(unknown),Julie D. Horan,Margaret A. Foley,Kenneth K. Iwata,Stanley C. Gill,Frank C. Richardson,Karen Kelly	2
14	Recurrent ovarian carcinoma: diagnosis and second-line therapy. 1995 ·PubMed ·Michael Geary,Margaret A. Foley,(unknown),James Murphy,J. J. Fennelly	5

About Margaret A. Foley

Margaret A. Foley is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 14 papers that have together received 402 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Research Studies (4 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (365 citations), Oncology (245 citations) and Cancer Research (66 citations). Margaret A. Foley has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Julie D. Horan, Jiuzhou Wang, Nasser K. Altorki, Frances A. Shepherd, Karen Kelly, Mary O’Brien, Wilfried Eberhardt, Philip C. Hoffman, Piotr Serwatowski and Lucio Crinò. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact